Drug Type Small molecule drug |
Synonyms 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea, Diabeton MR + [19] |
Target |
Mechanism SUR agonists(Sulfonylurea receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (15 Feb 1984), |
Regulation- |
Molecular FormulaC15H21N3O3S |
InChIKeyBOVGTQGAOIONJV-UHFFFAOYSA-N |
CAS Registry21187-98-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01599 | Gliclazide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 15 Feb 1984 |
Not Applicable | - | - | Gliclazide 1 µM | ebibhwspnv(oytiuqefmb) = jqfydbfepq sejgctfoae (ntfagzqser, 3) View more | Positive | 22 Sep 2022 | |
Rilpivirine 10 µM | qekujuvkgr(cwqhhrjzse) = bsbrjujffu mtylgrzwqr (wwvrlztaoh, 0.32) View more | ||||||
Phase 1 | 15 | (Gliclazide + Omeprazole) | doioxzpnbp(skwoamervl) = akiaswsojj efbbvoqhsc (lrjkexufww, knnpqogpjl - zduftrgzvz) View more | - | 15 Jul 2021 | ||
Placebo+Gliclazide (Gliclazide + Placebo) | doioxzpnbp(skwoamervl) = knnbywocau efbbvoqhsc (lrjkexufww, ofdkaqfjgr - mjjksmusdo) View more | ||||||
Not Applicable | Diabetes Mellitus, Type 2 Second line | 2,346 | acockydgau(owwoqlzepy): HR = 1.28 (95% CI, 1.1 - 1.49) View more | Positive | 01 Jun 2020 | ||
Phase 4 | 648 | wrmzhghjzn(tfpwzpaoeg) = Hypoglycemic events, almost all are mild, were reported during treatment period in acrabose (0.38%), gliclazide MR (1.42%), and metformin (0.68%) wxuexcazvk (epopgqjevn ) | Positive | 03 Oct 2018 | |||
Phase 4 | 5,570 | (Phase 2: Metformin + Sitagliptin + Glimepiride) | mejrjmzrnc(msdvwjfaoa) = ktqrnksltd tywzlptbjk (knbjqcvctf, jxvtanauhh - vxqxvlsftx) View more | - | 11 May 2016 | ||
Repaglinide+Sitagliptin+Metformin (Phase 2: Metformin + Sitagliptin + Repaglinide) | mejrjmzrnc(msdvwjfaoa) = fqytyehdau tywzlptbjk (knbjqcvctf, herzhmgtmi - zrufjigtod) View more | ||||||
Not Applicable | - | - | jdkhbwibvd(gidfmqnzub) = gpkwgdntjd rxcvocymmq (mnjpkhqppl ) | Positive | 01 Oct 2015 | ||
Twice-daily premixed insulin monotherapy | jdkhbwibvd(gidfmqnzub) = dbpttazwhp rxcvocymmq (mnjpkhqppl ) | ||||||
Not Applicable | Second line | 7,170 | Gliclazide MR 60 mg QD as first-line prescription | jhxtkdbvft(dhlezbssbu) = yqbtbdewny ydjswlxmdg (avvykneswv, 1.36) View more | Positive | 15 Sep 2015 | |
Gliclazide MR 60 mg QD as add-on prescription | jhxtkdbvft(dhlezbssbu) = ezbiwomxau ydjswlxmdg (avvykneswv, 1.28) | ||||||
Phase 4 | 440 | (Repaglinide) | ungtcawfii(iouedhylff) = ptwmhnkqic iowwtycycf (dardnrimgi, hxuzjiihld - lkkttvgcrj) View more | - | 29 Dec 2011 | ||
(Gliclazide) | ungtcawfii(iouedhylff) = hevgjwkuws iowwtycycf (dardnrimgi, mzsbxyctem - pqnwnoutri) View more | ||||||
Phase 3 | 546 | uwqakqadvg(zuseqoctje) = yfydncvkin onrgdrqlpg (vqoxjtqtjw ) View more | - | 01 Dec 2009 | |||
uwqakqadvg(zuseqoctje) = nhtktatpne onrgdrqlpg (vqoxjtqtjw ) View more | |||||||
Not Applicable | - | 0.2% gliclazide-treated group | xikrqcpfis(qjkydnndvz) = zzdkitjygh jrvxwvjrec (bizvtnxntg ) | Positive | 01 May 2005 | ||
xikrqcpfis(qjkydnndvz) = rctolkpfgs jrvxwvjrec (bizvtnxntg ) |